Pleural Diseases Market

Market Overview:

The 7 major pleural diseases markets reached a value of US$ 2.7 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 4.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.8% during 2024-2034.

The pleural diseases market has been comprehensively analyzed in IMARC's new report titled "Pleural Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pleural diseases refer to a group of medical conditions that affect the pleura, which is the thin membrane that lines the lungs and the inside of the chest cavity. Pleurisy, pleural effusion, and pneumothorax are the three main types of this disorder. Pleurisy is an inflammation of the pleura that often causes sharp chest pain during breathing. Pleural effusion refers to the accumulation of excessive fluid in the space between the two layers of the pleura, whereas pneumothorax is the presence of air or gases in the pleural cavity, which leads to a partial or complete collapse of the lung. The common symptoms include shortness of breath, fatigue, rapid heart rate, coughing, etc. The diagnosis of pleural diseases often involves a combination of medical history evaluation, physical examination, and imaging tests. Blood workups may be performed to check for markers of infection or inflammation that may be contributing to the underlying indications. The healthcare provider may also conduct a thoracoscopy, which helps in visualizing the pleura and ruling out other possible causes among patients.

The rising cases of infections, such as pneumonia and tuberculosis, that can cause inflammation or the accumulation of fluid and pus in the pleural space are primarily driving the pleural diseases market. Besides this, the increasing prevalence of chest trauma, like rib fractures, which can puncture or lacerate the lung tissues and disrupt the normal drainage mechanisms of the pleura, is also propelling the market growth. Additionally, the widespread adoption of various corticosteroids and nonsteroidal anti-inflammatory drugs to reduce inflammation as well as manage symptoms of the ailment is acting as another significant growth-inducing factor. Apart from this, the escalating application of pleurodesis techniques, in which a sclerosing agent is injected into the affected site to create adhesions between the two layers of the pleura, thereby preventing the recurrence of fluid or air accumulation, is also bolstering the market growth. Furthermore, the emerging popularity of video-assisted thoracoscopic surgery on account of its several advantages over traditional open surgeries, such as minimal invasion, shorter hospital stays, reduced postoperative pain, etc., is expected to drive the pleural diseases market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the pleural diseases market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for pleural diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pleural diseases market in any manner.

Recent Developments:

• In June 2024, RS Oncology announced positive results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from their Phase 1 research in patients with Malignant Pleural Mesothelioma (MPM) with Malignant Pleural Effusion (MPE) or MPE associated with other solid tumors.
• In February 2024, RS Oncology announced the first patient dosed in phase 2 clinical study (MITOPE) investigating RSO-021 for the treatment of MPE and metastatic disease to the lung.

Key Highlights:

• Pleurisy, pleural effusion, and pneumothorax are the three main pleural diseases.
• With an incidence of 360 cases per 100,000 people, the number of cases is likely to rise globally.
• Pleural effusion is the most prevalent pleural space disease, impacting 1.5 million individuals each year in the United States.
• In the United States, around 15,000 cases of spontaneous pneumothorax are reported each year.

Drugs:

Steritalc (purified talc) powder is a sclerosing agent used to reduce the recurrence of malignant pleural effusions in symptomatic patients after maximal drainage, as well as to reduce the recurrence of pneumothorax in adults. The recommended dose of Steritalc powder for malignant pleural effusion is 2 to 5 grams injected intrapleurally. The suggested dose of Steritalc powder for pneumothorax is 2 grams injected intrapleurally.

LTI-01 is the first pharmacological drug designed exclusively for treating non-draining loculated pleural effusion (LPE). LTI-01 has completed a Phase 1b clinical trial that showed early indicators of efficacy and no safety concerns. LTI-01 is a proenzyme, or zymogen, that degrades the fibrinous adhesions that cause LPE. LTI-01 has shown longer and more sustained activity than fibrinolytics taken off-label.

RSO-021 is an innovative small molecule therapy that permanently binds to mitochondrial peroxiredoxin 3 (PRX3). Preclinical investigations with RSO-021 have revealed that inhibiting the antioxidant signaling network selectively kills malignant cells by increasing oxidative stress, while healthy cells are spared.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the pleural diseases market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the pleural diseases market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current pleural diseases marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the pleural diseases market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2034?
• What was the country-wise size of the pleural diseases market across the seven major markets in 2024 and what will it look like in 2034?
• What is the growth rate of the pleural diseases market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of pleural diseases across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pleural diseases by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pleural diseases by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with pleural diseases across the seven major markets?
• What is the size of the pleural diseases patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of pleural diseases?
• What will be the growth rate of patients across the seven major markets?
   

Pleural Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for pleural diseases drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pleural diseases market?
• What are the key regulatory events related to the pleural diseases market?
• What is the structure of clinical trial landscape by status related to the pleural diseases market?
• What is the structure of clinical trial landscape by phase related to the pleural diseases market?
• What is the structure of clinical trial landscape by route of administration related to the pleural diseases market?